Angiotensin; Related Peptides Patents (Class 530/316)
-
Patent number: 11428574Abstract: Biomarkers of high blood pressure are measured to identify high blood pressure of the subject based on one or more biomarkers. In many embodiments, the response of the biomarker to blood pressure occurs over the course of at least an hour, such that the high blood pressure identification is based on a cumulative effect of physiology of the subject over a period of time. The methods and apparatus of identifying high blood pressure with biomarkers have the advantage of providing improved treatment of the subject, as the identified biomarker can be related to an effect of the high blood pressure on the subject, such as a biomarker corresponding to central blood pressure. The sample can be subjected to increases in one or more of pressure or temperatures, and changes in the blood sample measured over time.Type: GrantFiled: December 19, 2017Date of Patent: August 30, 2022Assignee: NUEON INC.Inventors: Robert G. Messerschmidt, Howland D. T. Jones
-
Patent number: 8999338Abstract: The invention relates to a method for diagnosis of multiple sclerosis (MS) wherein, presence or absence of an anti-AT1 receptor antibody is determined in a sample from a patient to be diagnosed and wherein, the presence of an anti-AT1-receptor antibody is indicative of the disease.Type: GrantFiled: April 12, 2011Date of Patent: April 7, 2015Assignee: Celltrend GmbHInventor: Harald Heidecke
-
Publication number: 20140303082Abstract: In the past decade a great deal of structural information for class A-GPCRs (G protein-coupled receptors) has emerged. However, the structural and electronic basis of ligand selectivity for closely related receptor subtypes such as the angiotensin receptors AT1aR and AT2R, which present completely diverse biological functions in response to the same ligand, is poorly understood. In order to monitor complex responses in biosystems it is useful to have ligands that present a gradient in terms of selectivity. In this study we present an efficient method to tune ligand selectivity for the two angiotensin II receptor subtypes, AT1aR and AT2R, by controlling aromatic-prolyl interactions in angiotensin II, through alternation of aromatic electronics. On the basis of this strategy, an AT2R selective and high affinity agonist analogue (Ki=3 nM) was obtained.Type: ApplicationFiled: June 20, 2014Publication date: October 9, 2014Inventor: Andreas Tzakos
-
Patent number: 8835375Abstract: The invention relates to analogs of angiotensins, in particular to cyclised analogs having Ang(1-8) agonistic or antagonistic activity and to cyclised Ang(1-7) analogs with agonistic or antagonistic activity and displaying improved proteolytic resistance compared to their linear counterparts. Provided is a cyclic angiotensin peptide analog comprising a thioether-bridge linkage between the amino acids corresponding to positions Tyr4 and Pro7 in naturally occurring Angiotensin. Also provided is the use of analogs in therapy, for example hypertension.Type: GrantFiled: August 7, 2007Date of Patent: September 16, 2014Assignee: Applied Nanosystems B.V.Inventors: Marijke Haas, Leonardus Dorothea Kluskens, Anneke Kuipers, Rick Rink, Sieger Adriaan Nelemans, Gert Nikolaas Moll
-
Publication number: 20140073760Abstract: The present invention refers to a peptidic or non-peptidic angiotensin(1-7) (Ang-(1-7)) receptor agonist, preferably a Mas receptor agonist, for the prevention and/or treatment of acute lung injury, preferably acute respiratory distress syndrome.Type: ApplicationFiled: June 28, 2013Publication date: March 13, 2014Applicant: Charite-Universitatsmedizin BerlinInventors: Thomas Walther, Wolfgang Kuebler
-
Publication number: 20130323751Abstract: This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease may be tailored depending upon the need for, or expectation of, renal recovery. For example, renal recovery can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, a normalized time course of approximately fourteen Days measuring urinary proteins can be used to establish the risk of recovery versus non-recovery in patient's having suffered an acute kidney injury. Alternatively, the invention describes signature protein expression profiles to establish the probability of renal to recovery and/or renal non-recovery.Type: ApplicationFiled: January 20, 2012Publication date: December 5, 2013Applicant: University of Pittsburgh - of the Common-Wealth System of Higher EducationInventors: Kai Singbartl, John A. Kellum, JR.
-
Patent number: 8580557Abstract: The present invention relates to a casein hydrolysate containing free amino acids and in vivo indigestible peptides having minimally suppressed in vivo enzymatic digestibility, and expected to express functions, such as hypotensive effect, in living organism, and to a method for preparing such a hydrolysate, and use thereof. The casein hydrolysate of the present invention contains free amino acids and peptides, such as in vivo indigestible peptides including Xaa-Pro and Xaa-Pro-Pro, obtained by hydrolyzing animal milk casein to have an average chain length of not longer than 2.1 in terms of the number of amino acid residues, and has ACE inhibitory activity or hypotensive effect.Type: GrantFiled: September 1, 2010Date of Patent: November 12, 2013Assignee: Calpis Co., Ltd.Inventors: Naoyuki Yamamoto, Seiichi Mizuno, Takanobu Gotou, Keiichi Matsuura, Tadashi Shinoda, Hideo Nishimura
-
Publication number: 20130296252Abstract: Provided are MUC18 targeting peptides which may be used, e.g., to therapeutically target B-1 lymphocytes to reduce the influence of these cells on the metastatic potential of melanoma cells and/or to target cancerous cells, including certain melanoma and leukemia cells. MUC18 targeting peptides may be comprised in fusion constructs, imaging constructs, and/or therapeutic constructs such as fusion constructs which may be used for diagnosing or treating a cancer.Type: ApplicationFiled: April 29, 2013Publication date: November 7, 2013Inventors: Fernanda STAQUICINI, Renata PASQUALINI, Wadih ARAP
-
Patent number: 8575111Abstract: The present invention relates to the use of Ang-(1-7) and/or Ang-(1-7) receptor agonist and/or Ang (1-7) analogue in treating/restoring erectile dysfunction.Type: GrantFiled: January 24, 2008Date of Patent: November 5, 2013Assignee: Universidade Federal de Minas Garais-UFMGInventors: Robson Augusto Souza dos Santos, Ruben Dario Sinisterra Millan, Frederic Jean Georges Frezard, Andrey Christian da Costa Goncalves, Rodrigo Araujo Fraga da Silva
-
Patent number: 8557958Abstract: The present invention relates to compositions and methods for treatment and/or prevention of diabetes or pre-diabetes. In particular, the invention provides compositions and methods for the treatment and/or prevention of diabetes or pre-diabetes, based on the use of angiotensin-(1-7) peptides, functional equivalents thereof, and/or angiotensin (1-7) agonists.Type: GrantFiled: February 1, 2013Date of Patent: October 15, 2013Assignee: Tarix Pharmaceuticals Ltd.Inventor: Richard Franklin
-
Patent number: 8536231Abstract: The present invention provides methods and pharmaceutical formulations for treating diabetic foot ulcers.Type: GrantFiled: May 9, 2012Date of Patent: September 17, 2013Inventors: Kathleen E. Rodgers, Gere S. diZerega
-
Publication number: 20130183367Abstract: The present invention is related to the peptide Des-[Asp1]-[Ala1]-Angiotensin-(1-7) (Ala1-Arg2-Val3-Tyr4-Ile5-His6-Pro7) and/or its related compounds as vasodilating and cardioprotective agents to be used in mammals. This invention also comprises the production of compositions containing Des-[Asp1]-[Ala1]-Angiotensin-(1-7) and/or its related compounds and its use in methods for treating and preventing diseases.Type: ApplicationFiled: February 13, 2009Publication date: July 18, 2013Inventors: Robson Augusto Souza dos Santos, Anderson José Ferreira, Rubén Dario Sinisterra, Rodrigo Araújo Fraga da Silva, Roberto Queiroga Lautner
-
Publication number: 20130095082Abstract: The present disclosure generally relates to the use of des-aspartate-angiotensin I and/or its derivatives in medicine. In particular, the present invention relates to the use of des-aspartate-angiotensin I and/or its derivatives for the treatment and/or prophylaxis of inflammatory diseases or pathologies, for inducing anti-inflammatory actions and/or reducing inflammation, and/or for treatment of inflammation-related conditions.Type: ApplicationFiled: June 8, 2011Publication date: April 18, 2013Inventor: Meng Kwoon Sim
-
Patent number: 8207233Abstract: The present invention provides methods and pharmaceutical formulations for treating diabetic foot ulcers.Type: GrantFiled: February 1, 2012Date of Patent: June 26, 2012Assignee: University of Southern CaliforniaInventors: Kathleen E. Rodgers, Gere S. diZerega
-
Patent number: 8207234Abstract: The present invention provides methods and pharmaceutical formulations for treating diabetic foot ulcers.Type: GrantFiled: April 6, 2012Date of Patent: June 26, 2012Assignee: University of Southern CaliforniaInventors: Kathleen E. Rodgers, Gere S. diZerega
-
Publication number: 20110081371Abstract: The present invention provides conjugates of peptide derivatives of the mammalian peptide hormones angiotensinogen, angiotensin I and angiotensin II, presented in a repetitive scaffold by coupling the peptide derivatives to a carrier, particularly a virus-like particle (VLP). The invention also provides methods of producing such conjugates, and immunotherapeutic uses of the resulting immunogen conjugates for the therapy and prophylaxis of conditions associated with the renin-activated angiotensin system.Type: ApplicationFiled: December 30, 2009Publication date: April 7, 2011Applicant: Cytos Biotechnology AGInventor: Martin Bachmann
-
Publication number: 20100233783Abstract: Process for purifying a recombinant protein including one or a few procedural steps only. The process combines the step of lysis of the host cell, with the purification of the protein of interest, allowing for a rapid and much more efficient process of purification. The conditions used during the purification process are those of a high temperature and a low pH, allowing for thermostable and acid-resistant recombinant proteins to be isolated from a suspension. The invention also relates to purifying recombinant proteins which are fusion proteins, wherein one part of the protein may be selected from an enamel matrix protein, such as amelogenin.Type: ApplicationFiled: March 23, 2006Publication date: September 16, 2010Applicant: Straumann Holding AGInventors: Johan Per Henrik Svensson, Leif Bülow
-
Patent number: 7786085Abstract: The present invention provides improved methods, kits, and pharmaceutical compositions for increasing hematopoietic cell survival and/or reducing or preventing the side effects of chemotherapy, and mobilizing hematopoietic progenitor cells from bone marrow into peripheral blood following chemotherapy, comprising administering an effective amount of angiotensinogen, angiotensin I (AI), AI analogues, AI fragments and analogues thereof, angiotensin II (AII), AII analogues, AII fragments or analogues thereof or AII AT2 type 2 receptor agonists to a patient in need of chemotherapy.Type: GrantFiled: January 11, 2008Date of Patent: August 31, 2010Assignee: University of Southern CaliforniaInventors: Kathleen Rodgers, Gere DiZerega
-
Publication number: 20100191096Abstract: The present invention relates to complexes comprising one or more marker(s) and one or more biomolecules. The complexes according to the present invention have a variety of utilities, such as utility as a contrast agent in imaging methods, for example magnetic resonance imaging.Type: ApplicationFiled: June 6, 2008Publication date: July 29, 2010Inventor: Olav Tenstad
-
Patent number: 7749725Abstract: The present invention relates to a method for screening drugs for use in treating hypertension using the tubular renin-angiotensinogen system identified by the present invention. The invention further relates to a method to diagnose sodium status and sensitivity in an individual by measuring urinary angiotensinogen or angiotensin-I.Type: GrantFiled: October 16, 2002Date of Patent: July 6, 2010Assignee: University of Utah Research FoundationInventors: Andreas Rohrwasser, Terry Morgan, Jean-Marc Lalouel
-
Publication number: 20100144624Abstract: We describe preparation of compounds of an AT1 receptor antagonist(s) and Angiotensin (1-7), for example, Angiotensin-(1-7) losartanate and analogues thereof, and/or mixtures of these systems, pharmaceutical compositions thereof and use of their derivative products. Cyclodextrins and derivatives thereof may be used for the micro-encapsulation of compounds, for example, Angiotensin (1-7) losartanate, liposomes and biodegradable polymers and/or mixtures of these systems and/or derivative products for the obtainment of nano- or microparticles as controlled or sustained release devices of Ang-(1-7) losartanate and analogues and/or mixtures thereof. The compounds may be used as agents for treating or preventing hypertension, cardiovascular diseases, heart hypertrophy, heart failure, coronary diseases, such as angina pectoris, endothelial disorder or endothelial lesions, as a consequence, for example, of atherosclerosis processes or in association with diabetes mellitus.Type: ApplicationFiled: October 30, 2006Publication date: June 10, 2010Inventors: Rubén Dario SinisterraMillán, Cynthia Fernades Ferreira Santos, Robson Augusto Souza Dos Santos, Ivana Silva Lula, Frederico Barros De Sousa, Pedro Pires Goulart Guimaraes, Angelo Márcio Leite Denadai
-
Publication number: 20100055146Abstract: The invention relates to analogs of angiotensins, in particular to cyclised analogs having Ang(1-8) agonistic or antagonistic activity and to cyclised Ang(1-7) analogs with agonistic or antagonistic activity and displaying improved proteolytic resistance compared to their linear counterparts. Provided is a cyclic angiotensin peptide analog comprising a thioether-bridge linkage between the amino acids corresponding to positions Tyr4 and Pro7 in naturally occurring Angiotensin. Also provided is the use of analogs in therapy, for example hypertension.Type: ApplicationFiled: August 7, 2007Publication date: March 4, 2010Inventors: Marijke Haas, Leonardus Dorothea Kluskens, Anneke Kuipers, Rick Rink, Sieger Adriaan Nelemans, Gert Nikolaas Moll
-
Patent number: 7553928Abstract: The present invention relates generally to a method for the treatment and/or prophylaxis of renal-related disorders. More particularly, the present invention contemplates a method for the treatment and/or prophylaxis of glomerulosclerosis and/or end stage renal failure and/or related conditions. The method of the present invention is preferably practised by the administration of a derivative of angiotensin I. Generally, but not exclusively, the angiotensin I derivative exhibits anti-angiotensin II properties. In a preferred embodiment, the angiotensin I is des-Aspartate-angiotensin I or a derivative, homologue or analogue thereof. The present invention further contemplates compositions for use in the treatment and/or prophylaxis of renal-related disorders such as but not limited to glomerulosclerosis and/or end stage renal failure.Type: GrantFiled: October 11, 2002Date of Patent: June 30, 2009Assignee: National University of SingaporeInventors: Meng Kwoon Sim, Chorh Chuan Tan
-
Publication number: 20090105150Abstract: An angiotensin derivative comprising at least one angiotensin peptide moiety coupled to a peptide carrier-binding moiety which can be used for therapy and prophylaxis of conditions associated with the renin activated angiotensin system.Type: ApplicationFiled: April 24, 2008Publication date: April 23, 2009Applicant: Protherics Medicines Development LimitedInventors: James Francis Glover, Arthur Rushton, Phillip John Morgan, Stephen Clinton Young
-
Patent number: 7482171Abstract: The present invention relates to the discovery of novel genes encoding an angiotensin converting enzyme, Angiotensin Converting Enzyme-2 (ACE-2). The invention provides therapeutics, prognostic and diagnostics methods for treating blood pressure related disorders as well as various types of allergic conditions, among others. Also disclosed are screening assays for identifying compounds for treating and preventing these conditions.Type: GrantFiled: February 16, 2005Date of Patent: January 27, 2009Assignee: Millennium Pharmaceuticals, Inc.Inventors: Susan Acton, Keith E. Robison, Frank Y. Hsieh
-
Publication number: 20080227205Abstract: The invention provides methods and compositions for in vivo incorporation of non-naturally encoded amino acids into polypeptides by Pseudomonas species and strains derived therefrom. Also provided are compositions including proteins with non-naturally encoded amino acids made by Pseudomonas species and strains derived therefrom.Type: ApplicationFiled: June 2, 2006Publication date: September 18, 2008Applicant: AMBRX, INC.Inventor: Ho Sung Cho
-
Patent number: 7378489Abstract: An angiotensin derivative comprising at least one angiotensin peptide moiety coupled to a peptide carrier-binding moiety which can be used for therapy and prophylaxis of conditions associated with the renin activated angiotensin system.Type: GrantFiled: December 23, 1999Date of Patent: May 27, 2008Assignee: Protherics Medicines Development LimitedInventors: James Francis Glover, Arthur Rushton, Phillip John Morgan, Stephen Clinton Young
-
Patent number: 7338938Abstract: The present invention provides improved methods, kits, and pharmaceutical compositions for increasing hematopoietic cell survival and/or reducing or preventing the side effects of chemotherapy, and mobilizing hematopoietic progenitor cells from bone marrow into peripheral blood following chemotherapy, comprising administering an effective amount angiotensinogen, angiotensin I (AI), AI analogues, AI fragments and analogues thereof, angiotensin II (AII) AII analogues, AII fragments or analogues thereof or AII AT2 type 2 receptor agonists to a patient in need of chemotherapy.Type: GrantFiled: May 10, 2004Date of Patent: March 4, 2008Assignee: University of Southern CaliforniaInventors: Kathleen Rodgers, Gere diZerega
-
Patent number: 7335722Abstract: The invention discloses five peptides which can be used as angiotensin converting enzyme inhibitor. The subject invention also discloses a process for the preparation of the products having angiotensin converting enzyme inhibitory activity, which comprises the following steps: (a) adding protein hydrolase to the solution of chicken residues for reaction; (b) separating the chicken residues and liquid after the reaction of step (a) and collecting the separated liquid; and (c) drying the liquid obtained from step (b) to obtain the products.Type: GrantFiled: April 5, 2004Date of Patent: February 26, 2008Assignee: Food Industry Research and Development InstituteInventors: Yi-Hong Chen, Yung-Hsiang Yang, Yu-Hui Liu, Chien-Ti Chang, Hsiao-Hui Feng, Chu-Chin Chen
-
Patent number: 7288522Abstract: The present invention provides methods, compounds, pharmaceutical compositions, and kits for the augmentation of erythropoiesis by potentiating erythropoietin-induced differentiation with angiotensinogen, angiotensin I (AI), AI analogues, AI fragments and analogues thereof, angiotensin II analogues, AII fragments or analogues thereof or AII AT2 type 2 receptor agonists as a therapeutic adjunct. The method is useful for the treatment of congenital or acquired aplastic or hypoplastic anemia associated with chronic renal failure, end-stage renal disease, renal transplantation, cancer, AIDS, chemotherapy, radiotherapy, bone marrow transplantation and chronic diseases.Type: GrantFiled: September 8, 2000Date of Patent: October 30, 2007Assignee: The University of Southern CaliforniaInventors: Kathleen E. Rodgers, Gere DiZerega
-
Patent number: 7276251Abstract: A sustained-release drug composition consisting essentially of microparticles of hyaluronic acid having a high molecular weight or an inorganic salt thereof and a protein or peptide drug encased in said microparticles, wherein the average size of said microparticles ranges from 0.1 to 40 ?m.Type: GrantFiled: July 26, 2002Date of Patent: October 2, 2007Assignee: LG Life Sciences, Ltd., Inc.Inventors: Myung-Jin Kim, Sun-Jin Kim, Oh-Ryong Kwon
-
Patent number: 7176183Abstract: The present invention provides improved methods, kits, and pharmaceutical compositions for treating and preventing damage to mucosal tissue by administering an effective amount of angiotensinogen, angiotensin I (AI), AI analogues, AI fragments and analogues thereof, angiotensin II (AII), AII analogues, AII fragments or analogues thereof or AII AT2 type 2 receptor agonists to the subject.Type: GrantFiled: June 23, 2004Date of Patent: February 13, 2007Assignee: University of Southern CaliforniaInventors: Kathleen E. Rodgers, Gere S. diZerega
-
Patent number: 7125702Abstract: The invention is a process for the preparation of angiotensin converting enzyme (ACE) inhibitors and the use thereof.Type: GrantFiled: November 28, 2005Date of Patent: October 24, 2006Assignee: Council of Scientific and Industrial ResearchInventors: Lalitha Ramakrishna Gowda, Appu Rao Gopal Rao Appu Rao, Vishweshwariah Prakash
-
Patent number: 7118747Abstract: AT4 receptor agonists are potent activators of angiogenesis and can be used to treat diseases that are characterized by vascular insufficiency. AT4 receptor antagonists, which are potent inhibitors of angiogenesis, and can be used as anti-angiogenic agents for the treatment of cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerotic plaque formation, and any disease process that is characterized by excessive, undesired or inappropriate angiogenesis or proliferation of endothelial cells.Type: GrantFiled: September 30, 2003Date of Patent: October 10, 2006Assignees: Pacific Northwest Biotechnology Inc., Washington State University Research FoundationInventors: Joseph W Harding, John W Wright
-
Patent number: 6995236Abstract: An object of the present invention is to provide a protein useful as a sphingomyelin detecting probe, which specifically recognizes sphingomyelin and has low cytotoxicity. The present invention provides a protein which has an amino acid sequence having, as the amino acid sequence from the 1st to the 48th amino acid, the amino acid sequence from the 1st to the 48th amino acid in Lysenin 1, and as the amino acid sequence from the 49th to the 298th amino acid, the amino acid sequence from the 51st to the 300th amino acid in Lysenin 3; and a protein which is obtained by deleting N terminal and/or C terminal from earthworm toxins Lysenin 1 or 3, and which specifically recognizes sphingomyelin.Type: GrantFiled: May 6, 2002Date of Patent: February 7, 2006Assignee: RikenInventors: Toshihide Kobayashi, Etsuko Kiyokawa, Akiko Hasegawa
-
Patent number: 6989363Abstract: The present invention relates to the discovery of novel genes encoding an angiotensin converting enzyme, Angiotensin Converting Enzyme-2 (ACE-2). The invention provides therapeutics, prognostic and diagnostics methods for treating blood pressure related disorders as well as various types of allergic conditions, among others. Also disclosed are screening assays for identifying compounds for treating and preventing these conditions.Type: GrantFiled: September 30, 1998Date of Patent: January 24, 2006Assignee: Millennium Pharmaceuticals, Inc.Inventors: Susan L. Acton, Keith Earl Robison, Frank Y. Hsieh
-
Patent number: 6919314Abstract: The invention relates to a partial hydrolysate of whey protein which contains bioactive peptides but does not have a bitter flavor. The hydrolysate is carried out using selective enzymes which produce the active peptides and is terminated at a degree of hydrolysis before substantial bitter flavors are created. There are also described novel peptides and a method of reducing systolic blood pressure through the administration of the peptides.Type: GrantFiled: June 14, 1999Date of Patent: July 19, 2005Assignee: New Zealand Dairy BoardInventors: Ralf-Christian Schlothauer, Linda May Schollum, Anne Maria Singh, Julian Robert Reid
-
Patent number: 6762167Abstract: The present invention provides improved methods, kits, and pharmaccutical compositions for increasing hematopoietic cell survival and/or reducing or preventing the side effects of chemotherapy, and mobilizing hematopoietic progenitor cells from bone marrow into peripheral blood following chemotherapy, comprising administering an effective amount of angiotensinogen, angiotensin I (AI), AI analogues, AI fragments and analogues thereof, angiotensin II (AII), AII analogues. AII fragments or analogues thereof or AII AT2 type 2 receptor agonists to a patient in need of chemotherapy.Type: GrantFiled: November 27, 2000Date of Patent: July 13, 2004Assignee: University of Southern CaliforniaInventors: Kathleen E. Rodgers, Gere S. DiZerega
-
Patent number: 6730775Abstract: The present invention provides methods, kits, and pharmaceutical compositions for limiting scar or adhesion formation by administration of angiotensinogen, AI, AI analogues, and/or AI fragments and analogues thereof, AII analogues, AII fragments or analogues thereof, ACE inhibitors, AII AT2 type 2 receptor agonists, either alone or in combination with other compounds.Type: GrantFiled: March 22, 2000Date of Patent: May 4, 2004Assignee: University of Southern CaliforniaInventors: Kathleen E. Rodgers, Gere diZerega
-
Patent number: 6514941Abstract: The present invention relates, in general, to a casein hydrolysate, and, in particular, to a method of preparing a casein hydrolysate enriched in antihypertensive peptides.Type: GrantFiled: December 17, 1999Date of Patent: February 4, 2003Assignee: Campina Melkunie B.V.Inventors: J. Kelly Tolton, II, Ram Nimmagudda, Steven D. Braun, Michael Primmer, Frans van der Veerdonk
-
Patent number: 6495338Abstract: The present invention relates to a method for screening drugs for use in treating hypertension using the tubular renin-angiotensinogen system identified by the present invention. The invention further relates to a method to diagnose sodium status and sensitivity in an individual by measuring urinary angiotensinogen or angiotensin-I.Type: GrantFiled: September 3, 1999Date of Patent: December 17, 2002Assignee: University of Utah Research FoundationInventors: Andreas Rohrwasser, Terry Morgan, Jean-Marc Lalouel
-
Patent number: 6444646Abstract: Angiotensin II Type 2 receptor agonists (AT2 receptor subtype agonists) are useful in accelerating wound healing. These compounds form the basis of compositions useful for accelerating wound healing, in which the active agent is present in an amount effective to accelerate wound healing. Preferably, the compositions are in the form of matrical or micellar solutions.Type: GrantFiled: February 14, 2000Date of Patent: September 3, 2002Assignee: University of Southern CaliforniaInventors: Kathleen Elizabeth Rodgers, Gere Stodder Dizerega
-
Patent number: 6335195Abstract: The present invention provides methods, improved cell culture medium and kits for promoting hematopoietic and mesenchymal stem and lineage-specific cell proliferation and differentiation by growth in the presence of angiotensinogen, angiotensin I (AI); AI analogues, AI fragments and analogues thereof, angiotensin II (AII), AII analogues, AII fragments or analogues thereof or AII AT2 type 2 receptor agonists, either alone or in combination with other growth factors and cytokines.Type: GrantFiled: January 23, 1998Date of Patent: January 1, 2002Assignee: Maret CorporationInventors: Kathleen E. Rodgers, Gere S. DiZerega
-
Patent number: 6239109Abstract: The present invention provides methods, compounds, pharmaceutical compositions, and kits for the augmentation of erythropoiesis by potentiating erythropoietin-induced differentiation with angiotensinogen, angiotensin I (AI), AI analogues, AI fragments and analogues thereof, angiotensin II analogues, AII fragments or analogues thereof or AII AT2 type 2 receptor agonists as a therapeutic adjunct. The method is useful for the treatment of congenital or acquired aplastic or hypoplastic anemia associated with chronic renal failure, end-stage renal disease, renal transplantation, cancer, AIDS, chemotherapy, radiotherapy, bone marrow transplantation and chronic diseases.Type: GrantFiled: February 8, 1999Date of Patent: May 29, 2001Assignee: University of Southern CaliforniaInventors: Kathleen E. Rodgers, Gere DiZerega
-
Patent number: 6197505Abstract: The present invention provides methods for assessing cardiovascular status in an individual, which comprise determining the sequence at one or more polymorphic positions within the human genes encoding angiotensin converting enzyme (ACE), angiotensinogen (AGT), and/or type 1 angiotensin II receptor (AT1). The invention also provides isolated nucleic acids encoding ACE, AGT, and AT1 polymorphisms, nucleic acid probes that hybridize to polymorphic positions, kits for the prediction of cardiovascular status, and nucleic acid and peptide targets for use in identifying candidate cardiovascular drugs.Type: GrantFiled: March 27, 1998Date of Patent: March 6, 2001Assignee: Pyrosequencing ABInventors: Leif Torbjörn Norberg, Maria Kristina Andersson, Per Harry Rutger Lindström
-
Patent number: 6177407Abstract: The present invention provides methods and kits for increasing blood flow to ischemic tissue, comprising the administration of an effective amount of angiotensinogen, angiotensin I (AI), AI analogues, AI fragments and analogues thereof, angiotensin II (AII), AII analogues, AII fragments or analogues thereof or AII AT2 type 2 receptor agonists.Type: GrantFiled: August 13, 1999Date of Patent: January 23, 2001Assignee: University of Southern CaliforniaInventors: Kathleen E. Rodgers, Gere DiZerega
-
Patent number: 6110895Abstract: Angiotensin II angiotensin II fragments, angiotensin II analogs, Angiotensin II Type 2 receptor agonists, angiotensin I or analogs thereof, and angiotensin or analogs thereof are useful in promoting the incorporation of skin grafts into the underlying tissue of the animal.Type: GrantFiled: December 15, 1997Date of Patent: August 29, 2000Assignee: University of Southern CaliforniaInventors: Kathleen E. Rodgers, Gere S. DiZerega
-
Patent number: 6022696Abstract: A unique and novel angiotensin AT4 receptor and AIV ligand system for binding a small N-terminal hexapeptide fragment of Angiotensin II (referred to as AIV, with amino acid sequence Val.sub.1 -Tyr.sub.2 -Ile.sub.3 -His.sub.4 -Pro.sub.5 -Phe.sub.6 ; SEQ. ID. NO. 1) is disclosed. AIV ligand binds saturably, reversibly, specifically, and with high affinity to membrane AT4 receptors in a variety of tissues, including heart, lung, kidney, aorta, brain, liver, and uterus, from many animal species. The AT4 receptor is pharmacologically distinct from classic angiotensin receptors (AT1 or AT2). The system employs AIV or C-terminally truncated or extended AIV-like peptides (e.g., VYIHPFX; SEQ. ID. NO. 8) as the signaling agent, and the AT4 plasma membrane receptor as the detection mechanism. The angiotensin AT4 receptor and receptor fragments (including the receptor binding site domain) are capable of binding a VYIHPF (SEQ. ID. NO.Type: GrantFiled: April 2, 1998Date of Patent: February 8, 2000Assignee: Washington State University Research FoundationInventors: Joseph W. Harding, John W. Wright
-
Patent number: 6011015Abstract: Angiotensin II, or an analog thereof, can be used for promoting the fertilization of mammalian eggs. A method is disclosed for promoting in vitro fertilization of mammalian eggs using angiotensin II or a salt or an analogue thereof.Type: GrantFiled: December 11, 1996Date of Patent: January 4, 2000Assignee: Queen Mary & Westfield CollegeInventor: Gavin Paul Vinson
-
Patent number: 5972387Abstract: Modified hydrolyzed vegetable protein microspheres and methods for their preparation and use as oral delivery systems for pharmaceutical agents are described.Type: GrantFiled: November 21, 1994Date of Patent: October 26, 1999Assignee: Emisphere Technologies, Inc.Inventors: Sam J. Milstein, Evgueni N. Barantsevitch